The company is a civil engineering firm that primarily builds, repairs, and widens roads and bridges for government agencies and municipal bodies in Gujarat, India. It also develops commercial real estate projects like hotels and hospitals.
The company lacks a durable moat as evidenced by its low average ROCE of 5.9% and net margins of 2.3%, which are below the cost of capital. The business relies on competitive government tender bidding, which is a commodity service with no significant pricing power or scale advantage.
Management has failed to generate value for shareholders, with negative EPS growth and returns on equity significantly below inflation. Capital is frequently tied up in low-yielding projects, and the company maintains a high debt-to-equity ratio relative to its thin profitability.
The company's thin interest coverage finally gave way as the cost of debt outpaced its stagnant, low-margin revenue. The working capital stress observed in the negative cash conversion cycle became a liquidity trap, forcing the firm to take on more expensive promoter loans to stay afloat. Without any pricing power in the competitive bidding process, margins compressed further, and the lack of professional oversight following the auditor's resignation allowed operational inefficiencies to spiral into a permanent impairment of equity value.
RichFakir rates Akash Infraprojects Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Akash Infraprojects Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Akash Infraprojects Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Akash Infraprojects Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →